[HTML][HTML] Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function

BP McNamara, A Koutsouris… - The Journal of …, 2001 - Am Soc Clin Investig
BP McNamara, A Koutsouris, CB O'Connell, JP Nougayréde, MS Donnenberg, G Hecht
The Journal of clinical investigation, 2001Am Soc Clin Investig
The mechanisms by which enteropathogenic Escherichia coli (EPEC), an important cause of
diarrhea among infants in developing countries, induce symptoms are not defined. EPEC
have a type III secretion system required for characteristic attaching and effacing changes
that modify the cytoskeleton and apical surface of host cells. Infection of polarized intestinal
epithelial cell monolayers by EPEC leads to a loss of transepithelial electrical resistance,
which also requires the type III secretion system. We demonstrate here that EspF, a protein …
The mechanisms by which enteropathogenic Escherichia coli (EPEC), an important cause of diarrhea among infants in developing countries, induce symptoms are not defined. EPEC have a type III secretion system required for characteristic attaching and effacing changes that modify the cytoskeleton and apical surface of host cells. Infection of polarized intestinal epithelial cell monolayers by EPEC leads to a loss of transepithelial electrical resistance, which also requires the type III secretion system. We demonstrate here that EspF, a protein that is secreted by EPEC via the type III secretion system, is not required for quantitatively and qualitatively typical attaching and effacing lesion formation in intestinal epithelial cells. However, EspF is required in a dose-dependent fashion for the loss of transepithelial electrical resistance, for increased monolayer permeability, and for redistribution of the tight junction–associated protein occludin. Furthermore, the analysis of EPEC strains expressing EspF-adenylate cyclase fusion proteins indicates that EspF is translocated via the type III secretion system to the cytoplasm of host cells, a result confirmed by immunofluorescence microscopy. These studies suggest a novel role for EspF as an effector protein that disrupts intestinal barrier function without involvement in attaching and effacing lesion formation.
The Journal of Clinical Investigation